Does RISANKIZUMAB-RZAA Cause Mobility decreased? 324 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 324 reports of Mobility decreased have been filed in association with RISANKIZUMAB-RZAA. This represents 0.5% of all adverse event reports for RISANKIZUMAB-RZAA.
324
Reports of Mobility decreased with RISANKIZUMAB-RZAA
0.5%
of all RISANKIZUMAB-RZAA reports
7
Deaths
134
Hospitalizations
How Dangerous Is Mobility decreased From RISANKIZUMAB-RZAA?
Of the 324 reports, 7 (2.2%) resulted in death, 134 (41.4%) required hospitalization, and 2 (0.6%) were considered life-threatening.
Is Mobility decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB-RZAA. However, 324 reports have been filed with the FAERS database.
What Other Side Effects Does RISANKIZUMAB-RZAA Cause?
Psoriasis (6,896)
Drug ineffective (2,885)
Pain (2,584)
Fatigue (2,483)
Arthralgia (2,419)
Pruritus (2,311)
Covid-19 (2,145)
Death (1,700)
Fall (1,666)
Surgery (1,662)
What Other Drugs Cause Mobility decreased?
ADALIMUMAB (8,829)
ETANERCEPT (8,321)
METHOTREXATE (5,936)
ABATACEPT (4,519)
TOCILIZUMAB (4,403)
LEFLUNOMIDE (4,354)
HYDROXYCHLOROQUINE (4,105)
RITUXIMAB (4,067)
INFLIXIMAB (3,784)
TOFACITINIB (3,734)
Which RISANKIZUMAB-RZAA Alternatives Have Lower Mobility decreased Risk?
RISANKIZUMAB-RZAA vs RISDIPLAM
RISANKIZUMAB-RZAA vs RISEDRONATE
RISANKIZUMAB-RZAA vs RISEDRONIC ACID
RISANKIZUMAB-RZAA vs RISPERDAL
RISANKIZUMAB-RZAA vs RISPERDAL CONSTA